, Tracking Stock Market Picks
Enter Symbol:

down 99.92 %

NEUROGESX INC. (NGSX) rated Buy with price target $2.50 by Ladenburg Thalmann

Posted on: Tuesday,  Nov 1, 2011  9:25 AM ET by Ladenburg Thalmann

Ladenburg Thalmann rated Buy NEUROGESX INC. (OTCBB: NGSX) on 11/01/2011. Previously Ladenburg Thalmann rated Buy NEUROGESX INC. (OTCBB: NGSX) on 03/23/2010.,
when the stock price was $8.37. Since then, NEUROGESX INC. has lost 99.92% as of 08/27/2015's recent price of $0.01.
If you would have followed the previous Ladenburg Thalmann's recommendation on NGSX, you would have lost 99.92% of your investment in 1983 days.

NeurogesX, Inc. (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates and is developing new therapies based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company?s most advanced product candidate, Qutenza, a dermal patch containing a high concentration of synthetic capsaicin, is designed to manage pain associated with peripheral neuropathic pain conditions. The Company submitted to the United States Food and Drug Administration?s (FDA) an new drug application (NDA) for Qutenza for the management of pain associated with postherpetic neuralgia (PHN), in October 2008 which was filed by the FDA in December 2008. The Company's Products include Qutenza, NGX-1998, Acetaminophen Prodrugs (NGX-1576, NGX-9674, NGX-5752) and Opioid Prodrugs (NGX-6052).

Our Research Department takes a fresh, critical approach to analyzing primary sources and developing proprietary research. Many individuals, institutions, portfolio managers and hedge fund managers, on all levels, have been neglected by brokerage firms ignoring the demands for unbiased research. Ladenburg Thalmann provides a superior branded in-depth research product geared only to action-oriented investment ideas. Ladenburg Thalmann’s proprietary equity research tries to uncover crucial information before the rest of the Street. Our analysts concentrate on uncovered and under-covered stocks and have a small to mid-cap focus. We will not shy away from large cap names as long as we can bring value to our clients through timely, differentiated ideas.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/1/2011 9:25 AM Buy
1.05 2.50
as of 12/30/2011
1 Week down  -17.17 %
1 Month down  -10.86 %
3 Months down  -7.86 %
1 YTD down  -87.10 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/23/2010 8:25 AM Buy
8.37 16.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy